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fumarate and lamivudine in human im
drug monitoring..., Journal of MicrobAbstract Background/Purpose: Treatment response to switch regimens containing un-
boosted atazanavir and tenofovir disoproxil fumarate (TDF)/lamivudine guided by therapeutic
drug monitoring in human immunodeficiency virus-infected patients is rarely investigated.
Methods: Consecutive patients with plasma human immunodeficiency virus RNA
load < 200 copies/mL switching to unboosted atazanavir plus zidovudineelamivudine (cofor-
mulated), abacavirelamivudine (coformulated), or TDF/lamivudine > 3 months were included
for determinations of treatment response, plasma atazanavir concentrations, and single-
nucleotide polymorphisms of MDR1, PXR, and UGT1A1 genes from 2010 to 2014. Treatment fail-
ure was defined as either discontinuation of atazanavir for any reason or plasma viral load
 200 copies/mL within 96 weeks.
Results: During the study period, 128 patients switched to unboosted atazanavir with TDF/la-
mivudine (TDF group) and 186 patients switched to unboosted atazanavir with two other nucle-
oside reverse-transcriptase inhibitors (non-TDF group). There were no statistically significant
differences in the distributions of single-nucleotide polymorphisms of MDR1 (2677 and 3435),
PXR genotypes (63396), and UGT1A1*28 between the two groups. Recommended plasma ataza-
navir concentrations were achieved in 83.5% and 64.9% of the TDF group and non-TDF group,
respectively (p < 0.01). After a median follow-up duration of 96.0 weeks, treatment failure
occurred in 19 (14.9%) and 34 (18.3%) patients in the TDF group and non-TDF group, respec-
tively (pZ 0.60). Low-level viremia (40e200 copies/mL) before switch (adjusted hazard ratio,
2.12; 95% confidence interval, 1.12e4.01) and without therapeutic drug monitoring (adjusted
hazard ratio, 2.08; 95% confidence interval, 1.16e3.73) were risk factors for treatment failure.
Conclusion: Switch to unboosted atazanavir with TDF/lamivudine achieves a similar treatment
response to that with two other nucleoside reverse-transcriptase inhibitors in patients
achieving virological suppression with the guidance of therapeutic drug monitoring.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Protease inhibitors (PIs) boosted with ritonavir in combi-
nation with two nucleos(t)ide reverse-transcriptase in-
hibitors (NRTIs) are recommended antiretroviral regimens
with good virological efficacy and a high genetic barrier to
resistance.1e3 Boosted atazanavir and darunavir are
preferred for the initial treatment of human immunodefi-
ciency virus (HIV) infection because each has demonstrated
better lipid effects and tolerability than ritonavir-boosted
lopinavir.4e6 Despite being administered at a low dose
(100 mg), ritonavir can lead to lipid disturbances, glucose
intolerance, insulin resistance, liver enzyme elevations,
gastrointestinal symptoms, and body fat abnormalities7,8;
furthermore, the potential drugedrug interactions be-
tween ritonavir and nonantiretroviral medications may
potentially lead to clinically significant adverse events.9e11
Randomized clinical trials have demonstrated similar
virological efficacy between the switch regimens consisting
of unboosted atazanavir and those consisting of boosted
atazanavir in patients who had achieved suppression of HIV-
1 replication after initial therapy with boosted atazanavir-
containing regimens.12e15 Regimens containing unboosted
atazanavir may provide better efficacy in virological sup-
pression and improvement of lipid parameters, compared
with those containing other PIs such as boosted lopinavir,
boosted or unboosted indinavir, boosted or unboosted sa-
quinavir, and nelfinavir.16 These issues were especially
relevant to aging HIV-positive patients who are likely to
have polypharmacy.17ai M-S, et al., Treatment response
munodeficiency virus-1-infected
iology, Immunology and InfectionUnlike other NRTIs, tenofovir disoproxil fumarate (TDF)
is not recommended in combination with unboosted ata-
zanavir because TDF may decrease atazanavir concentra-
tions by 23e40%, although the mechanisms for this
interaction remain unclear.18e20 Lower plasma concentra-
tions and higher interindividual variability due to the
diverse distribution of genetic polymorphisms that are
responsible for variations of atazanavir pharmacokinetics in
different ethnic populations are the major concerns.21 In
the clinical setting, studies have revealed that coadminis-
tration with TDF was not associated with lower plasma
exposure to unboosted atazanavir.22,23 In terms of virolog-
ical response, others studies have suggested that a combi-
nation of TDF with unboosted atazanavir may be safe in
selected populations.23e25
In this study, we aimed to compare the treatment
response to a switch regimen of unboosted atazanavir in
combination with TDF and lamivudine versus regimens of
unboosted atazanavir with two other NRTIs with the infor-
mation provided with therapeutic drug monitoring (TDM)
and pharmacogenetic investigations.Methods
Study population
In this retrospective observational study, we included HIV-
infected adults aged 20e65 years who switched to
unboosted atazanavir plus two NRTIs after achievingto unboosted atazanavir in combination with tenofovir disoproxil
patients who have achieved virological suppression: A therapeutic
(2016), http://dx.doi.org/10.1016/j.jmii.2015.12.012
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+ MODELplasma HIV RNA load (PVL) < 200 copies/mL with combi-
nation antiretroviral therapy (cART) for .> 3 months at the
National Taiwan University Hospital in Taipei, Taiwan be-
tween 2010 and 2014. NRTIs were chosen with consider-
ation of full treatment history, comorbidity, and available
resources. Patients with a history of virological failure
while receiving PI-based cART or with HIV-1 strains
harboring resistance-associated mutations to PIs were
excluded. Patients who were taking any H2 blockers or
proton-pump inhibitors were also excluded. Patients were
evaluated every 12 weeks after the treatment switch for
> 3 months to assess their tolerance and adherence and to
undergo laboratory monitoring, including PVL, CD4 count,
renal and liver function, fasting glucose, total cholesterol,
and triglycerides. The study was approved by the
Research Ethics Committee of National Taiwan University
Hospital (registration no. 201103077RC) and the patients
gave written informed consent for TDM of
plasma atazanavir concentrations and pharmacogenetic
investigations.Measurement of plasma atazanavir concentration
TDM to measure plasma atazanavir concentrations was
performed in patients switching to unboosted atazanavir-
containing regimens after November 2011. After patients
had taken atazanavir for 2 weeks or longer, measurements
of plasma atazanavir concentrations, C12 (12  1 hour
after intake) or C24 (24  1 hour after intake) based on
feasibility, were performed during their routine clinic
visits using high-performance liquid chromatography
(HPLC) with a modified method reported by Mu¨ller et al.26
Blood samples were collected into potassium and ethyl-
enediaminetetraacetic acid-containing 10-mL tubes.
Plasma was stored at 20C prior to analysis. In brief,
400 mL of plasma was added to 400 mL of 2M sodium car-
bonate containing diazepam (internal standard). The
resulting solution was extracted with 800 mL of ethyl
acetate-n-hexane, 1:1 (vol/vol), and the organic layer was
dried under nitrogen. The extract was then dissolved with
200 mL of methanol for HPLC analysis. The HPLC system
consisted of a L-2130 HTA solvent delivery pump, a L-2200
autosampler, a L-2420 UV-Vis detector, and the HPLC D-
2000 Elite on Windows (version 1.2, Hitachi High Tech-
nologies Corporation, Tokyo, Japan) chromatographic data
system. Chromatography was performed on a Mightysil RP-
18 GP column (250  4.6 mm, 5 mm; Kanto Corporation,
Portland, OR, USA). The mobile phase was composed of
10mM phosphate buffer (pH 2.5) mixed with acetonitrile
at a ratio of 58:42 (vol/vol), and the flow rate was 1 mL/
min. The detection wavelength was at 245 nm. The in-
jection volume was 20 mL. The retention time of ataza-
navir and internal standard was 11.95 minutes and
16.4 minutes, respectively. The calibration curve of ata-
zanavir was linear over the range of 100e10000 ng/mL.
The extraction recovery was 104%. The accuracy ranged
from 94.0% to 104.0%. The peak area of the intra- and
interassay coefficients of variation at 5000 ng/mL ranged
from 1.22e3.5% and 0e1.19%, respectively.Please cite this article in press as: Tsai M-S, et al., Treatment response
fumarate and lamivudine in human immunodeficiency virus-1-infected
drug monitoring..., Journal of Microbiology, Immunology and InfectionPharmacogenetic study
Single nucleotide polymorphisms [SNPs; multidrug resis-
tance 1 (MDR1) 2677G->T/A, MDR1 3435C->T, and preg-
nane X receptor (PXR) 63396C->T] were reported to be
associated with atazanavir concentrations, and differences
in the frequencies of common alleles encoding these pro-
teins among different ethnic groups can be related to the
variability in drug response.21,27,28 For example, the MDR1
G2677/T/A polymorphism was more common in Asians
(83e88%) than in Caucasians (67e69%).21,29,30 In this study,
DNA samples extracted from peripheral blood specimens
were obtained from participants. MassARRAYiPLEX Gold-
SNP Genotyping was then performed to determine the
SNPs of transcription factor binding sites of PXR regulatory
regions and MDR1 (ABCB1), while uridine diphosphate-
glucuronosyltransferase 1A1 (UGT1A1) UGT1A1*28 were
determined by methods described previously by Beutler
et al.31
Assessment of treatment outcomes
Patients were divided into two groups according to NRTIs
prescribed: TDF-based group in which patients received
TDF, lamivudine, and unboosted atazanavir; and non-TDF-
based group in which patients received coformulated
zidovudine/lamivudine or abacavir/lamivudine and
unboosted atazanavir. The primary outcome of interest was
time-to-treatment failure, which was defined as virological
failure (PVL  200 copies/mL) confirmed by a second test
within 3 months; or regimen modification or discontinuation
for any reason (intention-to-treat analysis), with the first
date of PVL  200 copies/mL or the date of regimen
modification as the failure date. The secondary primary
outcome was treatment failure by 24 weeks and 48 weeks.
Participants who did not experience the endpoint event
were censored at the time of 96 weeks.
Absolute changes in lipid levels from baseline were
summarized by treatment regimens through the last on-
study visit or the visit when a lipid-lowering agent was
added for the two groups of patients. Lipid data were
excluded from analyses after the initiation of lipid-lowering
agents.
Baseline characteristics and pharmacogenetic factors
were assessed for the association with the occurrence of
Grades 3e4 hyperbilirubinemia that was defined as a total
bilirubin > 2.5 times the upper limit of normal after a
switch to unboosted atazanavir.
Statistical analysis
Categorical data were analyzed using Chi-square test or
Fisher’s exact tests as appropriate, and continuous vari-
ables, expressed as median and interquartile range, were
compared using the ManneWhitney U test. Paired t-test
was used to analyze within-subject means over the two test
conditions. The regression models were built using a for-
ward stepwise procedure using demographic characteris-
tics, clinical characteristics that included hepatitis B virusto unboosted atazanavir in combination with tenofovir disoproxil
patients who have achieved virological suppression: A therapeutic
(2016), http://dx.doi.org/10.1016/j.jmii.2015.12.012
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included virological response to the prior cART, and CD4
counts. Logistic regression analysis was used to test pre-
dictive factors associated with Grades 3e4 hyper-
bilirubinemia. The confidence interval (CI) was set at 95%.
All statistical tests were 2-tailed, and p values < 0.05 were
considered to be statistically significant. The analysis was
conducted using the statistical package SAS 9.4 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Patient characteristics
During the study period, 314 patients who switched to
unboosted atazanavir in combination with two NRTIs were
included: 128 (40.8%) switched to TDF, lamivudine plus
unboosted atazanavir; and 186 (59.2%) to abacavir/lam-
ivudine (n Z 161) or zidovudine/lamivudine (n Z 25) plus
unboosted atazanavir. Baseline characteristics of both
groups of patients are shown in Table 1. Compared with
patients in the non-TDF group, patients in the TDF group
were younger (38.7 years vs. 43.0 years, p < 0.01), had a
higher proportion of chronic HBV infection (28.9% vs. 14.0%,
p < 0.01), and lower fasting triglycerides (139.5 mg/dL vs.
222.0 mg/dL, p < 0.01) and total cholesterol levels
(168.5 mg/dL vs. 213.5 mg/dL, p < 0.01) before the switch.Table 1 Baseline characteristics of 314 patients who switched t
reverse-transcriptase inhibitors.a
Characteristics Total (n Z 314)
Male sex 297 (94.6)
Age (y) 40.7 (33.9e46.9)
Weight (kg) 65.0 (59.0e73.0)
BMI (kg/m2) 22.4 (20.8e24.9)
Mode of transmission
MSM 234 (74.5)
Heterosexual 57 (18.2)
IDU 14 (4.5)
Unknown 9 (2.8)
HBsAg-positive 63 (20.1)
Anti-HCV-positive 22 (7.0)
CD4 cell count at switch (cells/mm3) 526 (370e682)
HIV-1 RNA < 40 copies/mL at switch 270 (86.0)
Triglycerides (mg/dL) 188.0 (109.0e329.0)
Total cholesterol (mg/dL) 188.5 (157.0e232.0)
Antiretroviral regimens before switching
Boosted atazanavir þ 2 NRTIs 124 (39.5)
Boosted PI (nonatazanavir) þ 2 NRTIs 79 (25.2)
Raltegravir þ 2 NRTIs 2 (0.64)
NNRTI þ 2 NRTIs 95 (30.3)
3 NRTIs 14 (4.5)
a Comparisons of continuous data are made using the ManneWhitney
c2 test.
Data are presented as n (%) or median (interquartile range).
BMIZ body-mass index; HBsAgZ hepatitis B surface antigen; HCVZ
sex with men; NRTIZ nucleos(t)ide reverse-transcriptase inhibitor; N
inhibitor.
Please cite this article in press as: Tsai M-S, et al., Treatment response
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drug monitoring..., Journal of Microbiology, Immunology and InfectionThe proportion of patients having achieved PVL< 40
copies/mL before the switch was 83.6% and 87.6% in the
TDF group and non-TDF group, respectively (p Z 0.32).
Within-class substitution, from boosted PIs to unboosted
atazanavir, was the most common switch strategy, espe-
cially in the TDF group. Deintensification from a ritonavir-
boosted atazanavir-containing regimen to unboosted
atazanavir-containing regimen was more common in the
TDF group (67.2% vs. 20.4%, p < 0.01; Table 1).Treatment response
After a median follow-up for 96 weeks (25th quartile,
74.0 weeks; 62.4% censored at Week 96), 53 (16.9%) expe-
rienced treatment failure. By Week 24, four patients (3.1%)
in the TDF group and 12 (6.5%) in the non-TDF group
experienced treatment failure (Chi-square test, pZ 0.19);
and by Week 48, 10 (7.8%) in the TDF group and 19 (10.2%)
in the non-TDF group experienced treatment failure (Chi-
square test, pZ 0.48). There was no statistically significant
difference between the two groups in time-to-treatment
failure at Week 96 (14.9% vs. 18.3%, log-rank p Z 0.60;
Figure 1). Results of Cox proportional hazards model
including all listed covariables are shown in Table 2. Inde-
pendent risk factors for treatment failure included low-
level viremia (40e200 copies/mL) before the switcho unboosted atazanavir in combination with two nucleos(t)ide
Tenofovir
group (n Z 128)
Nontenofovir
group (n Z 186)
p
121 (94.5) 176 (94.6) 0.97
38.7 (32.1e43.5) 43.0 (34.9e48.9) <0.01
65.1 (58.0e72.6) 64.0 (60.0e73.0) 0.44
22.5 (20.5e24.8) 22.3 (20.9e24.9) 0.56
0.18
102 (79.7) 132 (71.0)
16 (12.5) 41 (22.0)
6 (4.7) 8 (4.3)
4 (3.1) 5 (2.7)
37 (28.9) 26 (14.0) <0.01
10 (7.8) 12 (6.5) 0.64
516 (355e665) 530 (393e696) 0.37
107 (83.6) 163 (87.6) 0.32
139.5 (96.0e221.0) 222.0 (128.5e393.5) <0.01
168.5 (145.0e202.0) 213.5 (167.5e250.0) <0.01
<0.001
86 (67.2) 38 (20.4)
17 (13.3) 62 (33.3)
0 (0) 2 (1.1)
23 (18.0) 72 (38.7)
2 (1.6) 12 (6.5)
U test and categorical variables using either Fisher’s exact test or
hepatitis C virus; IDUZ injecting drug user; MSMZ men who have
NRTIZ nucleoside reverse transcriptase inhibitor; PIZ protease
to unboosted atazanavir in combination with tenofovir disoproxil
patients who have achieved virological suppression: A therapeutic
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Figure 1. Time-to-virological failure in patients who
switched to unboosted atazanavir plus two nucleos(t)ide
reverse-transcriptase inhibitors (tenofovir-based vs. non-
tenofovir-based regimens). TDF Z tenofovir disoproxil
fumarate.
Table 3 Reasons for treatment failure in both groups of
patients.
Reasons Tenofovir-
based (n Z 19)
Nontenofovir-
based (n Z 34)
Plasma HIV RNA
load > 200 copies/mL
5 (26) 15 (44)
Discontinuation of
atazanavir
14 (74) 19 (56)
Loss to follow up 2 (11) 7 (21)
Irregular dosing interval 4 (21) 5 (15)
Jaundice 3 (16) 5 (15)
Alopecia 1 (5.2) 0
Elevated serum
creatinine and
proteinuria
2(10) 0
Unknown 2(10) 2 (6)
Data are presented as n (%).
HIV Z human immunodeficiency virus.
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without TDM (AHR, 2.08; 95% CI, 1.16e3.73).
Reasons for treatment failure of the 53 patients are
summarized in Table 3. Twenty patients, including five
(3.9%) in the TDF group and 15 (8.1%) in the non-TDF group,
experienced virological failure (PVL  200 copies/mL)
during follow-up. Using KaplaneMeier analysis, no statisti-
cally significant difference was found in time to virological
failure between the two groups (p Z 0.18). The adjusted
Cox proportional hazards model revealed that low-level
viremia before switch was a predictive factor of virolog-
ical failure (AHR, 3.46; 95% CI, 1.34e8.92). No emergence
of resistance-associated mutations to atazanavir or NRTIs
was detected in the HIV-1 strains from the patients who
experienced virological failure.Lipid profile and hyperbilirubinemia
After the switch to unboosted atazanavir plus two NRTIs,
both groups showed similarly significant decrease of the
total cholesterol levels from baseline: 16.6 mg/dL (95%
CI, 11.8e21.4) in the TDF group and 23.2 mg/dL (95%Table 2 Univariate and multivariate analysis for factors associa
Variables Reference
Tenofovir-based Non-tenofo
Age (y) Per 1-y inc
HBsAg-positive HBsAg-neg
Anti-HCV-positive Anti-HCV-n
CD4 count (cells/mL) before switch Per 100-ce
Baseline plasma HIV RNA load (HIV RNA, 40e200
copies/mL)
HIV RNA <
Without therapeutic drug monitoring With thera
monitoring
a HRs and 95% CIs were calculated using Cox regression analysis.
CI Z 95% confidence interval; HBsAg Z hepatitis B surface antigen;
HR Z hazard ratio.
Please cite this article in press as: Tsai M-S, et al., Treatment response
fumarate and lamivudine in human immunodeficiency virus-1-infected
drug monitoring..., Journal of Microbiology, Immunology and InfectionCI, 15.7e30.7) in the non-TDF group (p Z 0.14). A sig-
nificant decrease in fasting triglycerides was also found
after the switch in both groups: 58.1 mg/dL (95% CI,
25.9e90.3) in the TDF group and 99.4 mg/dL (95% CI,
43.1e155.6) in the non-TDF group (p Z 0.21). During
the study period, 23.2% of the patients experienced Grades
3e4 hyperbilirubinemia (32.8% and 16.7% for TDF and non-
TDF group, respectively). In patients who switched from
boosted atazanavir to unboosted atazanavir, the total bili-
rubin levels decreased from 2.48 mg/dL to 2.13 mg/dL
[difference, 0.31 (95% CI, 0.43e0.17)] in the TDF group
(n Z 86) and from 2.17 mg/dL to 1.80 mg/dL [difference,
0.37 (95% CI, 0.74e0.12)] in the non-TDF group
(nZ 38). In multivariate analysis, age (per 1-year increase,
adjusted odds ratio 1.05; 95% CI, 1.01e1.09; p < 0.01) and
HBV coinfection (adjusted odds ratio 2.73; 95%CI,
1.02e7.29; pZ 0.04) were the two independent predictors
of Grades 3e4 hyperbilirubinemia.
Plasma atazanavir concentrations
TDM of atazanavir concentrations (C12 and C24) were
conducted in 197 patients (62.7%; TDF group vs. non-TDFted with virological failure in 314 patients.a
HR 95% CI p HR 95% CI p
vir-based 0.87 0.49e1.52 0.61
rease 1.01 0.98e1.03 0.65
ative 1.10 0.58e2.10 0.76
egative 0.75 0.24e2.42 0.64
ll/mL increase 0.97 0.87e1.08 0.56
40 copies/mL 2.08 1.11e3.90 0.02 2.12 1.12e4.01 0.02
peutic drug 2.00 1.16e3.43 0.01 2.08 1.16e3.73 0.01
HCV Z hepatitis C virus; HIV Z human immunodeficiency virus;
to unboosted atazanavir in combination with tenofovir disoproxil
patients who have achieved virological suppression: A therapeutic
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Table 4 Genotyping results of the patients who switched
to unboosted atazanavir in combination with tenofovir and
lamivudine (tenofovir-based group) or two other non-
tenofovir nucleoside reverse-transcriptase inhibitors (non-
tenofovir-based group).
Genotype Total Tenofovir
group
Nontenofovir
group
p
UGT1A1*28
(n Z 196)
0.71
TA6/TA6 154 (78.6) 82 (79.6) 72 (77.4)
TA6/TA7 42 (21.4) 21 (20.4) 21 (22.6)
TA7/TA7 0 0 0
MDR1 2677
(n Z 169)
0.54
G/G 46 (27.2) 18 (26.1) 28 (28.0)
G/T 62 (36.7) 25 (36.2) 37 (37.0)
G/A 22 (13.0) 10 (14.5) 12 (12.0)
T/A 21 (12.4) 6 (8.7) 15 (15.0)
T/T 17 (10.1) 9 (13.0) 8 (8.0)
A/A 1 (0.6) 1 (1.5) 0 (0)
MDR1 3435
(n Z 122)
0.47
C/C 12 (9.8) 3 (7.5) 9 (11.0)
C/T 89 (73.0) 32 (80.0) 57 (69.5)
T/T 21 (17.2) 5 (12.5) 16 (19.5)
PXR 63396
(n Z 122)
0.79
C/C 22 (18.0) 6 (15.0) 16 (19.5)
C/T 55 (45.1) 18 (45.0) 37 (45.1)
T/T 45 (36.9) 16 (40.0) 29 (35.4)
Data are presented as n (%).
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+ MODELgroup, 80.5% vs. 50.5%, p < 0.01) and the results are shown
in Figure 2. No statistically significant differences in the
clinical characteristics were observed between the patients
who had undergone TDM and those who had not (data not
shown). In the TDF group, 16.5% (17/103) patients had
plasma atazanavir concentrations below the recommended
therapeutic values (230 ng/mL for C12 and 150 ng/mL for
C24),32 whereas in the non-TDF-based group, 35.1% (33/94)
had atazanavir concentrations below the recommended
therapeutic values (p < 0.01).
Pharmacogenetic study
The distributions of UGT1A1 genotypes, MDR1 genotype at
positions 2677 and 3435, and the PXR genotype at position
63396 are shown in Table 2. There were no statistically
significant differences in the clinical characteristics be-
tween the patients who had undergone genotyping for each
gene and those who had not (data not shown). The distri-
butions of SNPs of these three genes were similar between
the two groups. For example, UGT1A1 genotypes were
characterized in 196 patients, for which TA6/TA6 was noted
in 78.6%, TA6/TA7 in 21.4%, and TA7/TA7 in 0% (Table 4).
Subgroup analysis
When we limited the analyses to those with TDM (nZ 197),
we found that 12.2% of the patients experienced treatment
failure (10 of 103 in TDF group and 14 of 94 in non-TDF
group, Chi-square test, p Z 0.30). In Cox regression, con-
centration above the recommended target (AHR, 0.61; 95%
CI, 0.25e1.44), low-level viremia (AHR, 2.02; 95% CI,
0.74e5.53), and TDF-containing regimen (AHR, 0.79; 95%Figure 2. Plasma atazanavir concentrations, tenofovir/lamivudine þ unboosted atazanavir, and abacavir-lamivudine (or zido-
vudine-lamivudine) þ unboosted atazanavir.
Please cite this article in press as: Tsai M-S, et al., Treatment response to unboosted atazanavir in combination with tenofovir disoproxil
fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic
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+ MODELCI, 0.33e1.89) were not statistically significantly associated
with treatment failure at Week 96.
To explore whether there was evidence that the differ-
ence in treatment response depended on genetic charac-
teristics, a planned subgroup analysis was conducted and
the results were plotted (Figure 3). It did not suggest a
statistically significant advantage in terms of time to
treatment failure for either group.Discussion
In this study, we found that in HIV-positive patients on
suppressive antiretroviral therapy without documented
resistance-associated mutations to PIs, a switch to
unboosted atazanavir in combination with TDF and lam-
ivudine provided comparable antiviral effectiveness to
unboosted atazanavir with two other non-TDF NRTIs. A
switch to unboosted atazanavir-containing regimens resul-
ted in lower total cholesterol and triglycerides without
addition of lipid-lowering drugs.
In randomized controlled trials, regimens consisting of
unboosted atazanavir plus two NRTIs caused less hyper-
bilirubinemia and improvement of lipid profiles,12,14 which
are also observed in our study.While TDF is not recommended
to be combined with unboosted atazanavir, an ongoing open-
label randomized control trial (NCT01351740) will examine
the clinical effect of the potential drugedrug interactions
between TDF and unboosted atazanavir in HIV-positive pa-
tients achieving viral suppression. In the retrospectiveFigure 3. Forest plot showing the risk of virological failure accord
resistance 1; PXR Z pregnane X receptor.
Please cite this article in press as: Tsai M-S, et al., Treatment response
fumarate and lamivudine in human immunodeficiency virus-1-infected
drug monitoring..., Journal of Microbiology, Immunology and Infectionanalysis of 886 patients who switched to unboosted
atazanavir-containing regimens in an European multicenter
cohort collaboration, Pavie et al25 found that TDF used in
combination with unboosted atazanavir in 36.9% of the pa-
tients did not increase the risk of virological failure.
In our study, we found that the risk of virological failure
could be reduced by 50% with the information of TDM, and
atazanavir concentrations below recommended target
were not correlated with virological failure in patients with
TDM, which is in line with the finding of other studies.24,33
There was a higher proportion of our patients (75%) who
had atazanavir concentrations above the recommended
target, which suggests that pharmacogenetics or environ-
mental influences may influence plasma atazanavir con-
centration to a greater extent than the potential drugedrug
interaction. Our subgroup analyses consistently demon-
strated insignificant differences between TDF and non-TDF
groups regarding time-to-virological failure in patients with
virological suppression subdivided by genetic poly-
morphisms. Although the small sample size of the subgroups
is a concern, the results may help minimize the bias and
draw a robust conclusion.
Plasma atazanavir concentrations are associated with
atazanavir-related hyperbilirubinemia.24,34 Recent studies
also suggested that boosted atazanavir-containing regimens
are associated with an increased risk of clinically significant
renal stones or cholelithiasis.35e38 Therefore, TDM to opti-
mize drug levels and to minimize adverse effects can be
clinically relevant in the long-term successful management
of cART for HIV-positive patients. Our study is the first studying to subgroups. CIZ confidence interval; MDR1Z multidrug
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+ MODELto use TDM in a clinical care setting to minimize the adverse
impact of drugedrug interactions between atazanavir and
TDF on virological response and the long-term metabolic
effects of ritonavir. While more clinical and pharmacoge-
netic studies are warranted to confirm our findings, our
finding that use of TDM reduced risk of treatment failure
gives support to the use of TDM in management of patients
on regimens containing boosted atazanavir.
There are several limitations to our study. This is not a
randomized clinical trial, and selection bias is likely to have
occurred. Patients who were deemed highly adherent to
cART might be more likely to be switched to unboosted
atazanavir combined with lamivudine and TDF than to
unboosted atazanavir combined with two other non-TDF
NRTIs, which may lead to an underestimation of the risk of
virological failure in the TDF group. However, the two
groups of patients had similar baseline characteristics and
distributions of genetic factors on the whole, which may
help minimize the bias. Secondly, limited by the sample
size, our study was not powered to demonstrate the non-
inferiority of one regimen to another. Thirdly, most of the
patients were middle-aged men who have sex with men
and, therefore, the results may not be generalizable to all
HIV-positive patients. Fourthly, not all patients in this study
underwent TDM and genotyping. While our study was the
first study to address the clinical responses to unboosted
atazanavir in combination with TDF and lamivudine with
the information of drug concentrations and pharmacoge-
netics, the missing data on the plasma atazanavir concen-
trations preclude us from establishing a prediction model to
identify atazanavir levels that might optimize trade-offs
between virological responses and adverse effects. Fifthly,
the distributions of the SNPs that are related to metabolism
of atazanavir are likely to differ among different ethnic-
ities, and therefore, our data may not be generalizable to
ethnicities other than Taiwanese. Lastly, the observation
duration was not long enough and a longer duration of
follow-up is warranted to assess the durability of the
regimen in virological suppression.
Unboosted ataznavir in combination with TDF and lam-
ivudine is as effective as unboosted atazanavir in combi-
nation with two other NRTIs in patients who have achieved
virological suppression. This regimen may represent a
viable option in the treatment simplification strategies in
populations with access to TDM.Conflicts of interest
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